Project Details
Description
In this proposal, we will investigate the therapeutic properties of recombinant fusion protein directed to tumor-associated antigen, IL13Rα2, via scFv47 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120) in murine glioma models of disease.
The NeoTx will provide purified recombinant protein and corresponding negative control protein for analysis.
The Northwestern University (PI: Irina Balyasnikova) will perform validations of the activity of the recombinant protein in murine models of glioblastoma in vitro and in vivo.
The NeoTx will provide purified recombinant protein and corresponding negative control protein for analysis.
The Northwestern University (PI: Irina Balyasnikova) will perform validations of the activity of the recombinant protein in murine models of glioblastoma in vitro and in vivo.
| Status | Active |
|---|---|
| Effective start/end date | 12/1/20 → 11/30/21 |
Funding
- Neotx Holdings Ltd. (Agmt 12/01/20)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.